What Dicloflex SR Treats: Main Uses and Benefits

Dicloflex SR is commonly used in situations involving certain distressing symptoms by targeting the core manifestations of inflammatory and painful conditions. It is applied across therapeutic domains where additional symptomatic support is needed.

---

Managing Symptomatic Discomfort

This sustained-release medication is relevant in conditions characterized by periods of heightened symptoms such as Rheumatoid Arthritis and Osteoarthritis. It helps address symptom clusters that include persistent joint pain, swelling, and stiffness, which are symptoms related to inflammatory or irritative states. It is also considered relevant in conditions presenting with acute episodes, such as primary dysmenorrhea (menstrual pain), and may be part of symptomatic management for post-traumatic or postoperative discomfort.

The medication is commonly used to help with symptoms related to physical discomfort and systemic imbalance, including pain, inflammation, and fever when present. This supports patients during episodes of heightened discomfort and may help them cope more steadily with symptom fluctuations.

Quick Fact: Relief for Pain and Stiffness
Dicloflex SR may assist with maintaining functional stability and provides supportive relief when inflammatory symptoms interfere with routine activities. The sustained-release formulation is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

1. NIH DailyMed official label for Diclofenac Extended-Release

Official Eligibility and Non-Eligibility Rules

Dicloflex SR (Diclofenac Sustained-Release) eligibility is strictly defined by regulatory documents, focusing on established risks and patient demographics.

Classification	Population/Condition
Absolutely Contraindicated	Known Hypersensitivity to Diclofenac or NSAIDs; history of NSAID-induced asthma/allergic reactions; in the setting of CABG surgery; active GI bleeding, ulceration, or perforation; Severe Hepatic or Renal Failure; and established Congestive Heart Failure (NYHA Class II-IV), Ischemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.
Pregnancy Restriction	Contraindicated during the third trimester of pregnancy. Use after 20 weeks gestation is limited.
Age Restriction	The sustained-release formulation is not suitable or recommended for children and adolescents (typically under 18 years). Geriatric patients (ge 65 years) require particular caution.
Conditional Use	Caution is advised for patients with mild to moderate renal or hepatic impairment, uncontrolled hypertension, or pre-existing Ulcerative Colitis or Crohn’s Disease.

Eligibility is primarily restricted to the adult population, and use in any high-risk group is strictly prohibited by official labeling.

Interactions with other medicines and products

The interaction profile for Diclofenac Sodium is classified into Pharmacodynamic (PD) and Pharmacokinetic (PK) patterns as documented in regulatory sources.

---

Formal Restrictions and Contraindications

Diclofenac is strictly contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with alcohol or other systemic NSAIDs is officially advised against due to a significantly increased risk of serious gastrointestinal adverse events.

---

Pharmacodynamic (PD) Risk

Concomitant use with drugs that affect coagulation or the gastrointestinal lining, such as anticoagulants (e.g., Warfarin), anti-platelet agents, SSRIs, and systemic corticosteroids, results in an additive pharmacodynamic interaction that increases the overall risk of gastrointestinal bleeding or ulceration.

---

Pharmacokinetic (PK) Exposure Modification

Diclofenac's plasma concentration can be affected by CYP2C9 enzyme inhibitors. For instance, Voriconazole is officially documented to increase Diclofenac exposure by reducing its clearance. Conversely, Diclofenac reduces the renal clearance of certain co-administered drugs, resulting in increased serum concentrations of agents such as Lithium and Digoxin, and increasing the exposure and toxicity risk for Methotrexate.

---

Efficacy and Population Notes

Diclofenac may diminish the intended effects of ACE Inhibitors, ARBs, and Diuretics. This interaction, and the risk of adverse events in general, is officially noted to be heightened in elderly or renal-impaired patients.

Inhibition of Cyclooxygenase (COX) Enzymes

Dicloflex SR's mechanism of action involves the modulation of specific biological pathways at the molecular level. The active compound, diclofenac, functions as an inhibitor of the cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This interaction directly prevents the conversion of arachidonic acid into prostanoids, including prostaglandins, which are lipid mediators synthesized locally in response to cellular stimuli.

---

Modulation of Eicosanoid Signaling Cascades

The resulting reduction in prostaglandin synthesis modifies the eicosanoid signaling cascade. These lipid mediators normally modulate the activity of peripheral sensory receptors and contribute to an increase in vascular permeability and vasodilation. By suppressing their production, the drug induces changes in targeted pathway activity, which alters the dynamics of specific physiological responses. This action restricts the accumulation of pro-inflammatory eicosanoids, leading to the decreasing concentration of key inflammatory mediators within affected tissues.

How to use Dicloflex SR

Dicloflex SR (Diclofenac Sodium Sustained-Release) is prescribed for oral administration as a tablet and is intended to be used at the lowest effective dosage for the shortest duration necessary to manage symptoms.

---

Standard Administration Guidelines

Feature	Rule
Route of Administration	Oral administration only.
Standard Dosing Schedule	The standard daily dosage is 100 mg taken once daily. The maximum recommended daily dose for the sustained-release form is typically 100 mg.
Tablet Handling	The tablet must be swallowed whole with liquid and must not be crushed, chewed, or broken to preserve its sustained-release mechanism.
Timing in Relation to Meals	Recommended to be taken with or immediately after food to enhance gastrointestinal tolerability.

---

Procedural and Population-Specific Use

• Once-Daily Frequency: The sustained-release formulation is designed for once-daily dosing to maintain steady, prolonged systemic action over a 24-hour period.
• Dosing for Older Adults: Use of the lowest effective dose is relevant for older adults (the elderly), especially those who are frail or have low body weight.
• Duration: The continued necessity of treatment, particularly for long-term use, must be re-evaluated periodically to ensure the principle of shortest duration is observed.

Standard administration protocols involve a structured, once-daily schedule focused on preserving the tablet's integrity and administering the lowest necessary dose.

Dicloflex SR: Recent Clinical Evidence

Diclofenac Sodium Sustained Release (Dicloflex SR) is a non-steroidal anti-inflammatory drug (NSAID) designed to provide relief from symptoms associated with chronic inflammatory conditions. The sustained-release formulation aims to allow for less frequent dosing compared to immediate-release forms.

Efficacy in Chronic Pain Conditions

Clinical studies, primarily randomized controlled trials (RCTs), have been conducted to evaluate the symptomatic effects of Dicloflex SR in conditions where inflammation and pain are present.

• Osteoarthritis (OA): Research has examined the use of Dicloflex SR for managing pain and stiffness associated with knee and hip osteoarthritis. Studies typically measured patient-reported pain intensity and functional improvements over periods such as 4 to 12 weeks. Results from these trials generally indicated an improvement from baseline in these pain and function parameters, with no statistically significant difference often observed when compared to other reference NSAIDs.
• Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS): Clinical evidence also supports the evaluation of Dicloflex SR in the symptomatic treatment of rheumatoid arthritis and ankylosing spondylitis. Outcomes in these studies were assessed using measures of disease activity and patient global assessment.

Safety Considerations from Clinical Data

All oral diclofenac formulations, including sustained-release, carry known risks that have been documented across multiple trials and post-marketing data. Healthcare authorities recommend limiting the use of Dicloflex SR to the lowest effective dose for the shortest possible duration to mitigate potential serious adverse events.

System	Key Risk Observed in Diclofenac Studies
Cardiovascular	Associated with an increased risk of serious events, particularly at higher doses and with long-term use.
Gastrointestinal (GI)	Risk of GI bleeding, ulceration, and perforation.

Dicloflex SR only provides symptomatic relief and does not treat the underlying disease or prevent its progression. The overall benefit-risk profile is assessed by the prescribing physician based on the patient's individual health status and risk factors.

Key Studies & References

1. NICE Guideline NG21: Osteoarthritis in over 16s: diagnosis and management

Common questions about Dicloflex SR (FAQ)

---

Q: Can children or teenagers take Dicloflex SR?

According to official product information, the sustained-release formulation of Dicloflex SR is not suitable or recommended for children and adolescents, as indicated for this specific formulation.

---

Q: Is it safe to drink alcohol while I'm taking Dicloflex SR?

Official information advises against consuming alcohol while using this medicine. This is because official documents cite a significantly increased risk of serious gastrointestinal adverse events, such as bleeding or ulceration, when alcohol is combined with Dicloflex SR.

---

Q: What should I do if I accidentally take too much Dicloflex SR (overdose)?

Symptoms of an acute overdose may include nausea, vomiting, stomach pain, and potential gastrointestinal bleeding. If an overdose is suspected, official information directs patients to contact medical emergency services immediately for appropriate supportive care.

---

Q: How long does it take for Dicloflex SR to start working?

Dicloflex SR is a sustained-release formulation designed to release the active ingredient, diclofenac, gradually over time. The drug's pharmacokinetic properties show that peak plasma concentrations (the highest level in the bloodstream) are typically reached several hours after administration, supporting a prolonged effect.

---

Q: Can I drive or operate machinery after taking Dicloflex SR?

Caution is advised because official safety information reports that side effects such as dizziness, vertigo, or visual disturbances may occur with this medicine. If these effects occur, official information states that driving or operating machinery should be avoided.

Dicloflex SR (diclofenac sodium prolonged-release tablets) must be stored and handled according to specific official labeling instructions to maintain its quality and ensure safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25°C (some labels permit storage up to 30 C).
Protection	Protect the tablets from light and moisture.
Container	Store in the original package or in well-closed containers.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired Dicloflex SR must be disposed of safely. The official instruction is to discard the product according to local regulations, such as pharmaceutical take-back programs. Do not dispose of the tablets via household wastewater (e.g., sink or toilet) to prevent environmental release.